Core Insights - IQVIA Holdings reported quarterly earnings of 3.12pershare,exceedingtheZacksConsensusEstimateof3.10 per share, and up from 2.84pershareayearago,indicatinga9.863.96 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.89% and showing a year-over-year increase from 3.87billion[2]−IQVIAhasconsistentlyoutperformedconsensusEPSandrevenueestimatesoverthelastfourquarters,indicatingstrongoperationalperformance[2]EarningsOutlook−ThesustainabilityofIQVIA′sstockpricemovementwilllargelydependonmanagement′scommentaryduringtheearningscallandfutureearningsexpectations[3][4]−CurrentconsensusEPSestimatefortheupcomingquarteris2.59 on revenues of 3.85billion,whileforthecurrentfiscalyear,theestimateis11.80 on revenues of $16.02 billion [7] Industry Context - The Medical - Instruments industry, to which IQVIA belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]